These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36604418)

  • 1. Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition.
    Tocci P; Roman C; Sestito R; Di Castro V; Sacconi A; Molineris I; Paolini F; Carosi M; Tonon G; Blandino G; Bagnato A
    Cell Death Dis; 2023 Jan; 14(1):5. PubMed ID: 36604418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endothelin-1-driven tumor-stroma feed-forward loops in high-grade serous ovarian cancer.
    Tocci P; Roman C; Sestito R; Caprara V; Sacconi A; Molineris I; Tonon G; Blandino G; Bagnato A
    Clin Sci (Lond); 2024 Jul; 138(14):851-862. PubMed ID: 38884602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer.
    Sestito R; Tocci P; Roman C; Di Castro V; Bagnato A
    J Exp Clin Cancer Res; 2022 Apr; 41(1):157. PubMed ID: 35477522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer.
    Tocci P; Cianfrocca R; Di Castro V; Rosanò L; Sacconi A; Donzelli S; Bonfiglio S; Bucci G; Vizza E; Ferrandina G; Scambia G; Tonon G; Blandino G; Bagnato A
    Nat Commun; 2019 Jul; 10(1):3196. PubMed ID: 31324767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
    J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression.
    Cianfrocca R; Tocci P; Rosanò L; Caprara V; Sestito R; Di Castro V; Bagnato A
    Oncotarget; 2016 Apr; 7(14):17790-804. PubMed ID: 26909598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
    Kanakkanthara A; Hou X; Ekstrom TL; Zanfagnin V; Huehls AM; Kelly RL; Ding H; Larson MC; Vasmatzis G; Oberg AL; Kaufmann SH; Mansfield AS; Weroha SJ; Karnitz LM
    Cancer Res; 2022 Jan; 82(2):307-319. PubMed ID: 34810199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
    J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer.
    Chellini L; Caprara V; Spadaro F; Sestito R; Bagnato A; Rosanò L
    Matrix Biol; 2019 Aug; 81():17-33. PubMed ID: 30367951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process.
    Di Modugno F; Caprara V; Chellini L; Tocci P; Spadaro F; Ferrandina G; Sacconi A; Blandino G; Nisticò P; Bagnato A; Rosanò L
    Proc Natl Acad Sci U S A; 2018 Mar; 115(12):3132-3137. PubMed ID: 29439204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
    Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
    Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    Tan J; Zheng X; Li M; Ye F; Song C; Xu C; Zhang X; Li W; Wang Y; Zeng S; Li H; Chen G; Huang X; Ma D; Liu D; Gao Q
    Oncogene; 2021 Jun; 40(22):3845-3858. PubMed ID: 33966038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer.
    Cianfrocca R; Rosanò L; Tocci P; Sestito R; Caprara V; Di Castro V; De Maria R; Bagnato A
    Cell Death Differ; 2017 Oct; 24(10):1811-1820. PubMed ID: 28708138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer.
    Masi I; Ottavi F; Del Rio D; Caprara V; Vastarelli C; Giannitelli SM; Fianco G; Mozetic P; Buttarelli M; Ferrandina G; Scambia G; Gallo D; Rainer A; Bagnato A; Spadaro F; Rosanò L
    Cell Death Dis; 2023 Jan; 14(1):73. PubMed ID: 36717550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK.
    Masi I; Caprara V; Spadaro F; Chellini L; Sestito R; Zancla A; Rainer A; Bagnato A; Rosanò L
    Cell Rep; 2021 Mar; 34(9):108800. PubMed ID: 33657382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.